Anyone who closely follows this company knows the erratic and eccentric nature of its trading around earnings time. Fundamentally, nothing has changed. I dont see any slowdown in the drug consumption of our medicated society. These sell trades were stop triggers & weak hands as someone said earlier, not institutions. The company has a lot of cash on hand and is in a steady growth mode. An earnings meet of .27 is a 300+% increase over Q3 last year. I like my chances and the 10% discount.